TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05960175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New telemonitoring approach using 2 connected devices : Scanwatch connected watch + Asten&masanté application
Description: The home healthcare provider will monitor the treatment remotely and make home visits, as in the control group. However, in the case of technical alerts concerning CPAP treatment (problems with observance, leaks, residual apneas), the provider will send the patient a notification via the mobile application in order to provide advice/instructions so that the patient can resolve the alert independently. The provider will monitor the resolution of alerts remotely and may contact the patient by telephone or come to your home if necessary.~If the connected watch detects an abnormal heart rhythm at night, the patient receives a notification and can undergo an electrocardiogram.
Study: NCT05545137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pivmecillinam hydrochloride tablets
Description: 400mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin Tromethamine Granules
Description: 3g/pack
Study: NCT05820243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Aerobic Exercise
Description: Participants will complete 1 hour of exercise on a cycle ergometer at the power output that elicits 60% of their peak rate of oxygen consumption (V02peak).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moderate Intensity Aerobic Exercise
Description: Participants will complete 1 hour of exercise on a cycle ergometer at the power output that elicits 60% of their peak rate of oxygen consumption (V02peak).
Study: NCT06425198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days
Study: NCT06210776

Intervention type: DRUG
Intervention: Trastuzumab deruxtecan
Description: Intravenous infusion

Intervention type: DRUG
Intervention: Trastuzumab deruxtecan
Description: Intravenous infusion
Study: NCT04983862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Illuminare-1
Description: Illuminare-1 at 3 dose levels in patients undergoing minimally invasive radical prostatectomy and bilateral pelvic lymph node dissection. Dose levels of the agent will be administered starting at 0.25mg/kg, with increases in dose between cohorts of no more than 0.75 mg/kg until a maximum dose of 3.0mg/kg is reached, if needed. At the dose identified to have the acceptable NMR and no associated DLTs, Illuminare-1 will be studied in up to 20 additional patients at this dose to optimize the imaging protocol and provide additional safety data.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karl Storz D-Light C photodynamic diagnostic (PDD)
Description: The Storz PDD system will be used as the hardware system in this phase 1 study due to its proven safety profile.
Study: NCT06135389

Intervention type: BIOLOGICAL
Intervention: Titration of paracetamol and its metabolites - scheme1
Description: 15 to 20 minutes and 1 to 2 hours after first perfusion and before second perfusion/administration of paracetamol

Intervention type: BIOLOGICAL
Intervention: Titration of paracetamol and its metabolites - scheme 2
Description: 30 to 40' after first perfusion and before second perfusion/administration of paracetamol (residual concentration)
Study: NCT05256394

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Manager + tailored implementation support
Description: Individualized training, technical assistance, and workflow assessments.
Study: NCT03590821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: timed administration of aspirin in the evening
Study: NCT06480019

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interpersonal psychotherapy
Description: Interpersonal psychotherapy is a first-line treatment and can also be used for the prevention of depression.
Study: NCT03590821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: timed administration of aspirin in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg capsule
Description: daily administration of celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg capsule
Description: daily administration of celecoxib
Study: NCT05028634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus, diphtheria, and acellular pertussis vaccine
Description: Tdap

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus, diphtheria, and acellular pertussis vaccine
Description: Tdap

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus, diphtheria, and acellular pertussis vaccine
Description: Tdap

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus, diphtheria, and acellular pertussis vaccine
Description: Tdap

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine
Description: PPSV23

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine
Description: PPSV23
Study: NCT05851638

Intervention type: DEVICE
Intervention: Lung Oxygen measurement with GASMAS system
Description: A specially designed light source probe (2x2cm size) with 2x incorporated laser sources and a detector probe (2x2cm size) will be attached to the torso of the infant in a total of 10 locations to measure lung oxygen.
Study: NCT05028634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine
Description: PPSV23

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine
Description: PPSV23

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine
Description: Seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine
Description: Seasonal influenza vaccine
Study: NCT05027438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprescribing
Description: The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
Study: NCT05041803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Twice daily dosing
Study: NCT05349019

Intervention type: OTHER
Intervention: Observational
Description: This is an observational study to investigate the natural history of G2019S LRRK2 PD using traditional and digital methodology (digital phenotyping). Study conduct will be decentralized (at home as much as possible) consisting of two parts: Part A with Healthy Volunteers (HV) participants and Part B in patients with G2019S LRRK2 PD.

Intervention type: OTHER
Intervention: Observational
Description: This is an observational study to investigate the natural history of G2019S LRRK2 PD using traditional and digital methodology (digital phenotyping). Study conduct will be decentralized (at home as much as possible) consisting of two parts: Part A with Healthy Volunteers (HV) participants and Part B in patients with G2019S LRRK2 PD.

Intervention type: OTHER
Intervention: Observational
Description: This is an observational study to investigate the natural history of G2019S LRRK2 PD using traditional and digital methodology (digital phenotyping). Study conduct will be decentralized (at home as much as possible) consisting of two parts: Part A with Healthy Volunteers (HV) participants and Part B in patients with G2019S LRRK2 PD.

Intervention type: OTHER
Intervention: Observational
Description: This is an observational study to investigate the natural history of G2019S LRRK2 PD using traditional and digital methodology (digital phenotyping). Study conduct will be decentralized (at home as much as possible) consisting of two parts: Part A with Healthy Volunteers (HV) participants and Part B in patients with G2019S LRRK2 PD.
Study: NCT05930171

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided L-ESPB and PENG block using Bupivacaine
Description: Combined Lumbar Erector Spinae Plane Block and Pericapsular Nerve Group Block in Patients Undergoing Hip Surgeries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative conventional analgesia in form of Acetaminophen
Description: Postoperative conventional analgesia in form of acetaminophen 15 mg/kg/6hrs
Study: NCT04241913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mom Power Intervention
Description: Mom Power is a 10-week therapeutic intervention for at-risk families that incorporates elements of several evidence based practices. It combines didactic material with mindbody self-care skills and in vivo practice to improve the quality of attachment between parent and child, and to reduce the psychopathology of at-risk parents. The child team component provides each child with one-on-one care focusing on meeting the child's social-emotional needs and providing attachment-related experiences within a developmental framework.
Study: NCT06045000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC-806
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-DC-806
Description: Oral capsules
Study: NCT05820997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Paravertebral at the T7-10 levels bilaterally with 5 cc of 0.5% ropivacaine at each level
Study: NCT05509595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Burosumab
Description: Human recombinant monoclonal antibody to fibroblast growth factor-23 (FGF23)
Study: NCT06425926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIM-531
Description: GIM-531 administered orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIM-531
Description: GIM-531 administered orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Continued treatment with anti-PD-1 therapy
Study: NCT05530070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Patients will participate in a structured, group-based dietary counseling. Consultations will be organized online (Zoom meeting) lasting approximately 60 min/occasion. The intervention will include 6 sessions for 1 year (monthly for 5 months and finally at month 9). The aim of the counseling is to maintain a GFD and to develop a healthy lifestyle, in line with the Mediterranean diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients will receive standard of care and baseline dietary education.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular risk-related parameters
Description: Anthropometric measurements (body height, body composition assessment-InBody 770), questionnaires (symptoms, quality of life, dietary adherence, diet quality, cardiovascular risk), assessment of sarcopenia (handgrip dynamometer), urine collection (dietary adherence - urine gluten immunogenic peptide detection), blood collection (immunological tests, hormone levels complemented with routine laboratory panel), transabdominal US examination to assess the extent of fatty liver disease.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular risk-related parameters
Description: Anthropometric measurements (body height, body composition assessment-InBody 770), questionnaires (symptoms, quality of life, dietary adherence, diet quality, cardiovascular risk), assessment of sarcopenia (handgrip dynamometer), urine collection (dietary adherence - urine gluten immunogenic peptide detection), blood collection (immunological tests, hormone levels complemented with routine laboratory panel), transabdominal US examination to assess the extent of fatty liver disease.
Study: NCT05872477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Topical
Description: There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
Study: NCT05415124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemoPill
Description: The HemeoPill acute capsule is a small, single use, swallowable capsule with optical sensor. Blood detection by direct measurement of blood in the sensor gap, even in an unprepared digestive tract. Wireless transmission of measured values to the HemoPill Receiver. The maximum measuring time is 9 hours. The length of the capsule is 26.3 mm and the diameter is 7.0 mm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Endoscopy is performed as scheduled.
Study: NCT06304324

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium chloride
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1mg/kg Dexamethasone
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05ug/kg Dexmedetomidine
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.05ug/kg dexmedetomidine for the popliteal nerve block
Study: NCT05882214

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-nicotinamide Mononucleotide
Description: After an 8-hour overnight fast, the participants ingested β-nicotinamide Mononucleotide capsules with a single morning dose of 1000mg. The purity of β-nicotinamide Mononucleotide capsules was no less than 97% according to high-performance liquid chromatography analysis.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: After an 8-hour overnight fast, the participants ingested maltodextrin capsules with a single morning dose of 1000mg.
Study: NCT06261216

Intervention type: OTHER
Intervention: Interview
Description: * International Physical Activity Questionnaire (IPAQ-SF)~* interviewer-administered modified Lifetime Total Physical Activity Questionnaire (LTPAQ) form

Intervention type: OTHER
Intervention: Interview
Description: * International Physical Activity Questionnaire (IPAQ-SF)~* interviewer-administered modified Lifetime Total Physical Activity Questionnaire (LTPAQ) form

Intervention type: OTHER
Intervention: Interview
Description: * International Physical Activity Questionnaire (IPAQ-SF)~* interviewer-administered modified Lifetime Total Physical Activity Questionnaire (LTPAQ) form
Study: NCT05031780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Mitapivat tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Mitapivat tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Mitapivat tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Mitapivat tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Mitapivat tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mitapivat-matching placebo
Description: Placebo to match 50 mg or 100 mg tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mitapivat-matching placebo
Description: Placebo to match 100 mg tablets
Study: NCT05873504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Oscillatory Index Device
Description: This device is commonly used to provide assistance with airway secretion clearance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Oscillatory Index Device
Description: This device is commonly used to provide assistance with airway secretion clearance.
Study: NCT04680663

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral Perfusion index
Description: Peripheral Perfusion index is the ratio between pulsatile blood flow to non pulsatile blood flow or static blood in the peripheral tissue

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral Perfusion index
Description: Peripheral Perfusion index is the ratio between pulsatile blood flow to non pulsatile blood flow or static blood in the peripheral tissue

Intervention type: DIAGNOSTIC_TEST
Intervention: serum lactate level
Description: Blood lactate (product of metabolism) level is maintained by a cycle of continuous production and metabolism allowing it to be kept within normal values

Intervention type: DIAGNOSTIC_TEST
Intervention: serum lactate level
Description: Blood lactate (product of metabolism) level is maintained by a cycle of continuous production and metabolism allowing it to be kept within normal values
Study: NCT06309290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation with resistance-exercise training
Description: The volunteers in the intervention group will be subjected to 16 - 20 weeks of whole-body resistance-type exercise training (2x/wk).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care program
Description: The volunteers in the intervention group will be subjected to usual care (diagnosis confirmation, chemotherapy treatment planning and an initial education session).
Study: NCT04848038

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Standard public health exercise recommendations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Standard public health exercise recommendations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Standard public health exercise recommendations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Standard public health exercise recommendations
Study: NCT04781322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab is a human monoclonal antibody (IgG1) that binds to and inhibits PCSK9 and was approved by the FDA in July of 2015. PCSK9 binds to and promotes degradation of low-density lipoprotein receptors (LDLR) on hepatocyte membranes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Heavy drinking healthy volunteers
Study: NCT06550895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilta-cel
Description: Cilta-cel infusion will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilta-cel
Description: Cilta-cel infusion will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilta-cel
Description: Cilta-cel infusion will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered subcutaneously as a part of DRd induction therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally as a part of DRd induction therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally or intravenously as a part of DRd induction therapy.
Study: NCT06270173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)
Description: The Tripod-Fix is a permanent implant used for vertebral augmentation in patients with osteoporotic vertebral compression fractures.
Study: NCT05539469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ortodontika app
Description: parents will download and use Ortodontika smartphone application for all the duration of the study. It will be an aid during orthopedic treatment. During the activations, a notification will be set to remind the daily activation of RME. After the end of the activation protocol, parents will receive a notification every 2 weeks to instruct their children to proper oral hygiene maneuvers. Parents will have to show their children the videos for oral hygiene maintenance every 2 weeks until the end of the study.

Intervention type: OTHER
Group type: OTHER
Intervention: Verbal instructions
Description: verbal instructions will be given chairside to patients and parents regarding RME activation and its cleaning, together with instructions for daily oral hygiene manoeuvres.
Study: NCT06638229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The StimaWELL 120MTRS system
Description: A standardized current (dynamic deep wave stimulation) was applied to all patients. Additionally, the mat, which reached a temperature of 40°C, provided heat therapy with electrical stimulation
Study: NCT06308497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic Treatment
Description: Professional in-office debridement every 3 months Use of soft-picks® advanced interdental cleaners (Gum®) followed by toothbrushing with ActiVital toothpaste (Gum®) with coenzyme Q10 and sonic daily electric toothbrush (Gum®) twice a day Probiotic supplementation with daily assumption of Limosilactobacillus Reuteri Prodentis® tablet (PerioBalance, Gum®)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Professional in-office debridement every 3 months Use of soft-picks® advanced interdental cleaners (Gum®) followed by toothbrushing with ActiVital toothpaste (Gum®) with coenzyme Q10 and sonic daily electric toothbrush (Gum®) twice a day
Study: NCT06020014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604
Description: AZD4604

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05899036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RapidPulseTM Aspiration System
Description: The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the cerebral vasculature using pulsatile aspiration. The system is comprised of a sterile one-time use 071 catheter, a sterile one-time use tubing set and a multiuse aspiration pump console.